Physician profile
James H Petrin
NPI 1316948904
$15,594.91
in general payments reported to CMS, 2019-2025
25 companies · $4,404 in 2025
The $4,404 reported for 2025 was more than what 89% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $708 · 2020: $690 · 2021: $952 · 2022: $3,057 · 2023: $3,306 · 2024: $2,479 · 2025: $4,404.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,310 · Consulting Fee: $3,600 · Education: $279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,309.84 |
| Consulting Fee | $3,600.00 |
| Education | $278.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $5,273.02 | 2019-2025 | |
| Ucb, INC. | $2,851.31 | 2019-2025 | Bimzelx |
| Abbvie INC. | $1,962.64 | 2019-2025 | |
| Janssen Biotech, INC. | $1,022.94 | 2019-2025 | Tremfya, Remicade, Simponi Aria |
| Galderma Laboratories, L.P. | $738.92 | 2020-2025 | Nemluvio, Aklief |
| Regeneron Healthcare Solutions, INC. | $507.68 | 2022-2025 | Dupixent, Libtayo |
| Arcutis Biotherapeutics, INC. | $441.40 | 2023-2025 | Zoryve |
| Lilly USA, LLC | $430.42 | 2019-2025 | Taltz, Ebglyss, Zepbound |
| Genzyme Corporation | $362.30 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $302.36 | 2022-2025 | Sotyktu |
| Incyte Corporation | $292.06 | 2022-2025 | Opzelura |
| Amgen INC. | $220.03 | 2021-2022 | |
| Dermavant Sciences, INC. | $212.55 | 2023-2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $212.53 | 2020-2025 | Cabtreo, Siliq |
| Pfizer INC. | $204.26 | 2019-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $112.65 | 2019-2023 | Adbry |
| Organogenesis INC. | $98.95 | 2024-2025 | Via Matrix, Nushield |
| Sun Pharmaceutical Industries INC. | $74.18 | 2023-2024 | Winlevi |
| Biofrontera INC. | $62.46 | 2022-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Strata Skin Sciences, INC. | $47.77 | 2024-2025 | Xtrac |
| Organon LLC | $45.07 | 2025 | Vtama |
| Allergan, INC. | $39.16 | 2019 | |
| Pharming Healthcare, INC. | $30.29 | 2025 | Ruconest |
| Mimedx Group, INC. | $25.42 | 2024 | |
| Prugen, INC. Pharmaceuticals | $24.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Petrin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.